Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Bristol-Myers Squibb Company (NYSE:BMY)
- Dividend Yield: 4.29%
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 71%.
- Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 71%.
- Recent News: On March 24, Bristol Myers Squibb received positive CHMP opinion for subcutaneous formulation of Opdiv across multiple solid tumor indications.
- Benzinga Pro’s real-time newsfeed alerted to latest BMY news.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
- Dividend Yield: 4.70%
- Morgan Stanley analyst Erin Wright maintained an Overweight rating and cut the price target from $30 to $23 on Dec. 17, 2024. This analyst has an accuracy rate of 75%.
- UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $35 to $27 on Dec. 3, 2024. This analyst has an accuracy rate of 72%.
- Recent News: On March 17, Dentsply Sirona named David Ferguson as Global Business Unit Leader.
- Benzinga Pro's real-time newsfeed alerted to latest XRAY news
Viatris Inc. (NASDAQ:VTRS)
- Dividend Yield: 5.88%
- Piper Sandler analyst David Amsellem reiterated a Neutral rating and raised the price target from $13 to $14 on Dec. 6, 2024. This analyst has an accuracy rate of 73%.
- B of A Securities analyst Jason Gerberry downgraded the stock from Neutral to Underperform with a price target of $9 on Oct. 23, 2024. This analyst has an accuracy rate of 62%.
- Recent News: Viatris will report first quarter financial results on Thursday, May 8.
- Benzinga Pro’s real-time newsfeed alerted to latest VTRS news
Read More:
Photo via Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: dividend yieldNews Dividends Price Target Pre-Market Outlook Markets Analyst Ratings Trading Ideas
